Clinical Research

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

EAGAN, MN — December 4, 2019 — Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in chemo-refractory metastatic triple negative breast cancer patients have been selected for a poster discussion Spotlight Session on December 11 at the 2019 San Antonio Breast Cancer Symposium. Spotlight...

Read More


Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in triple negative breast cancer and melanoma this week at the Society for Immunotherapy of Cancer annual meeting in the Gaylord...

Read More


Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate (Three previous TNBC clinical studies with checkpoint inhibitor (CPI) monotherapies generated response rates of 5% to 6%) 25% Disease Control Rate >24 weeks 13.7 months median Overall Survival, with 64.2% patient survival at 12 months...

Read More


Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, MN — April 16, 2018 — Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).  These data provide the first evidence in human clinical trials that Imprime PGG-based therapy can activate the immune system...

Read More


Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

Big Ten Cancer Research Consortium conducting trial with funding from Merck EAGAN, MN — July 19, 2017 — Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second-line non-small cell lung cancer (NSCLC).  The University of Illinois...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More


Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More